Parkinson’s Cell Therapy Bemdaneprocel Shortens Off Time

People with Parkinson’s disease who received a new cell therapy called bemdaneprocel had fewer “off” periods—times when their symptoms were not well controlled by medication. According to final results from the Phase 1 exPDite trial, this therapy also increased the time patients spent with well-managed symptoms. What is bemdaneprocel? It’s a treatment where dopamine-producing nerve cells, created from human embryonic stem cells, are surgically implanted into the brain. These cells are meant to restore dopamine levels, which drop in Parkinson’s and cause symptoms. In the trial: 12 participants received either a low or high dose of the therapy. The cells were implanted into a brain area linked to movement (the putamen). Patients took medication to suppress immune reactions for one year. Key findings (18 months after treatment): Motor symptoms improved, especially in those who received the high dose. “On” time (good symptom control) increased more in the high-dose group. “Off” time decreased by up to 2.7 hours daily. Quality of life and ability to perform daily tasks improved in the high-dose group but worsened slightly in the low-dose group. There were no serious side effects, even two years after the procedure. Brain scans showed the transplanted cells survived and were active. The therapy did not significantly affect medication use or unwanted movements caused by levodopa. The company behind the therapy, Bluerock Therapeutics, plans to begin a Phase 3 trial (exPDite-2) soon to confirm these results. Experts say this trial offers hope for people with Parkinson’s, showing the potential of regenerative medicine to rebuild damaged brain networks.